Cell & Gene: The Podcast
Gene Therapy Deals, Collaborations, & Partnerships with Astellas' Richard Wilson
Nov 21, 2023
Richard Wilson, Senior VP at Astellas, discusses gene therapy deal-making, Astellas' strategic approach post Audentes acquisition, building gene therapy infrastructure, advancements in gene therapy, strategic focus areas like genetic regulation and immuno-oncology, and the importance of partnerships in the cell and gene therapy sector.
25:02
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Astellas aims to develop an end-to-end gene therapy unit focusing on platform, pipeline, and people.
- Gene therapy landscape expects major clinical data releases and global accessibility challenges in the coming months.
Deep dives
Stellis' Aim to Build a World-Class Gene Therapy Infrastructure
Stellis' ambition in gene therapy is to create an end-to-end business unit focused on translating genetic potential into marketed products to benefit patients. The three main areas of focus are platform, pipeline, and people. The company has a strong AAV platform and infrastructure supporting its pipeline growth, including partnerships with other companies like Kate Therapeutics and TASER gene therapies to enhance its offerings.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
